mezigdomide + dexamethasone

Mezigdomide + dexamethasone is an **all-oral combination regimen** under investigation for the treatment of **relapsed and refractory multiple myeloma**. Mezigdomide is a next-generation cereblon E3 ubiquitin ligase modulator (CELMoD) designed to induce degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), leading to anti-proliferative and tumoricidal activity, even in multiple myeloma resistant to prior immunomodulatory drugs. Mezigdomide acts by binding cereblon within the cullin 4A ring ligase complex (CRL4-CRBN), resulting in selective proteasomal degradation of substrate proteins. This modulates immune responses, enhances T cell activation, and induces apoptosis in myeloma cells. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and anti-tumor effects, widely used in myeloma regimens. In clinical trials, the combination has demonstrated promising efficacy and a tolerable safety profile in heavily pretreated, triple-class refractory patients, with main toxicities being hematologic (e.g., neutropenia, anemia)[1][3][4].

Other names

mezigdomide and dexamethasone